100 CAMPUS DRIVE, FLORHAM PARK, NJ
Earnings Release
Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refract
Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Other Events
News, Articles of Incorporation
Announces One-for-Thirty Reverse Stock Split
Shareholder votes
Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Q2
Q1
FY 2024
Q3
Notice of Late Filing for Quarterly Report
Amended Quarterly Report
Amended Annual Report
S-1
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership